Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Biomolecules|October 27, 2022
The Epigenetic Dimension of Protein Structure Is an Intrinsic Weakness of the AlphaFold ProgramFodil Azzaz, Nouara Yahi, Henri Chahinian, et al.
The Journal of Infection|June 5, 2021
Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating Covid-19 outbreaksJacques Fantini, Nouara Yahi, Fodil Azzaz, et al.
Life (Basel, Switzerland)|January 28, 2026
Serotonergic Signaling Rewired: A Lipid Raft-Controlled Model of Synaptic Transmission Grounded in the Fundamental Parameters of Biological SystemsJacques Fantini, Marine Lefebvre, Nouara Yahi, et al.
Biomolecules|January 28, 2026
The Enigmatic Conserved Q134-F135-N137 Triad in SARS-CoV-2 Spike Protein: A Conformational Transducer?Marine Lefebvre, Henri Chahinian, Nouara Yahi, et al.
Viruses|January 8, 2025
Characterization and Fluctuations of an Ivermectin Binding Site at the Lipid Raft Interface of the N-Terminal Domain (NTD) of the Spike Protein of SARS-CoV-2 VariantsMarine Lefebvre, Henri Chahinian, Bernard La Scola, et al.
International Journal of Antimicrobial Agents|April 7, 2020
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infectionJacques Fantini, Coralie Di Scala, Henri Chahinian, et al.
Glycoconjugate Journal|July 30, 2021
Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson's diseaseNouara Yahi, Coralie Di Scala, Henri Chahinian, et al.
Plos One|March 31, 2009
The insertion and transport of anandamide in synthetic lipid membranes are both cholesterol-dependentEric Di Pasquale, Henri Chahinian, Patrick Sanchez, et al.
International Journal of Molecular Sciences|September 28, 2024
Cholesterol-Dependent Serotonin Insertion Controlled by Gangliosides in Model Lipid MembranesJacques Fantini, Fodil Azzaz, Ryad Bennaï, et al.
Scientific Reports|March 18, 2025
Preclinical assessment of a ganglioside-targeted therapy for Parkinson's disease with the first-in-class adaptive peptide AmyP53Jacques Fantini, Fodil Azzaz, Anaïs Aulas, et al.
Pageof 6